Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Jacobin Pharma announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the...

Related Keywords

United States ,San Diego ,California ,American , ,American Association For Cancer Research ,Jacobin Pharma ,American Association ,Cancer Research ,Annual Meeting ,Poster Presentation ,Antitumor Agents ,